UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

60 Development of a gene signature to predict the anti-tumor response of the salt-inducible kinase (SIK) inhibitor OMX-0407

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A70-A70

2023

Volltextzugriff (PDF)

Metabolism and pharmacokinetics of oxazaphosphorines

Clinical pharmacokinetics, 2000-04, Vol.38 (4), p.291-304

2000

Volltextzugriff (PDF)

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Clinical cancer research, 2007-03, Vol.13 (6), p.1816-1822

2007

Volltextzugriff (PDF)

Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma

Clinical cancer research, 2004-01, Vol.10 (2), p.455-460

2004

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Clinical cancer research, 2003-11, Vol.9 (14), p.5195-5204

2003

Volltextzugriff (PDF)

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors

Clinical cancer research, 2015-01, Vol.21 (1), p.87-97

2015

Volltextzugriff (PDF)

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

Investigational new drugs, 2005-06, Vol.23 (3), p.225-234

2005

Volltextzugriff (PDF)

Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2559-2559

2018

Volltextzugriff (PDF)

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14531-e14531

2023

Volltextzugriff (PDF)

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

Oncogene, 2010-04, Vol.29 (16), p.2325-2336

2010

Volltextzugriff (PDF)

Abstract 953: Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.953-953

2023

Volltextzugriff (PDF)

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients

Investigational new drugs, 2005-08, Vol.23 (4), p.317-330

2005

Volltextzugriff (PDF)

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

European journal of cancer (1990), 2016-07, Vol.61, p.94-101

2016

Volltextzugriff (PDF)

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study

Clinical cancer research, 2015-01, Vol.21 (2), p.267-273

2015

Volltextzugriff (PDF)

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Blood, 2018-11, Vol.132 (Supplement 1), p.2672-2672

2018

Volltextzugriff (PDF)

A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21043-e21043

2018

Volltextzugriff (PDF)

Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.TPS43-TPS43

2018

Volltextzugriff (PDF)

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Blood, 2017-12, Vol.130, p.1375-1375

2017

Volltextzugriff (PDF)

Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7059-7059

2017

Volltextzugriff (PDF)

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

Clinical lymphoma, myeloma and leukemia, 2014-06, Vol.14 (3), p.223-230

2014

Volltextzugriff (PDF)

A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck

Clinical cancer research, 2004-07, Vol.10 (14), p.4680-4687

2004

Volltextzugriff (PDF)

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Blood, 2013-11, Vol.122 (21), p.1976-1976

2013

Volltextzugriff (PDF)

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1747-1747

2014

Volltextzugriff (PDF)

Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST)

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.105-105

2013

Volltextzugriff (PDF)

Cyclophosphamide metabolism in children

Cancer research (Chicago, Ill.), 1995-02, Vol.55 (4), p.803-809

1995

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(59)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Humans
(19)
Oncology
(14)
Male
(13)
Female
(12)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Aged
(7)
Antineoplastic Agents
(7)
Chemotherapy
(7)
Child
(7)
Middle Aged
(7)
Pharmacology. Drug Treatments
(7)
Adult
(6)
Antineoplastic Agents - Pharmacokinetics
(6)
Adolescent
(5)
Child, Preschool
(5)
Pharmacology & Pharmacy
(5)
Animals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

60 Development of a gene signature to predict the anti-tumor response of the salt-inducible kinase (SIK) inhibitor OMX-0407

Metabolism and pharmacokinetics of oxazaphosphorines

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

Abstract 953: Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC

Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST)

Cyclophosphamide metabolism in children

Suchergebnisse filtern